keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy induced peripheral neuropathy

keyword
https://www.readbyqxmd.com/read/29339292/selective-hcn1-block-as-a-strategy-to-control-oxaliplatin-induced-neuropathy
#1
F Resta, L Micheli, A Laurino, V Spinelli, T Mello, L Sartiani, L Di Cesare Mannelli, E Cerbai, C Ghelardini, M N Romanelli, G Mannaioni, A Masi
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is the most frequent adverse effect of pharmacological cancer treatments. The occurrence of neuropathy prevents the administration of fully-effective drug regimen, affects negatively the quality of life of patients, and may lead to therapy discontinuation. CIPN is currently treated with anticonvulsants, antidepressants, opioids and non-opioid analgesics, all of which are flawed by insufficient anti-hyperalgesic efficacy or addictive potential. Understandably, developing new drugs targeting CIPN-specific pathogenic mechanisms would dramatically improve efficacy and tolerability of anti-neuropathic therapies...
January 12, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29333020/oxaliplatin-induced-peripheral-neuropathy-in-south-indian-cancer-patients-a-prospective-study-in-digestive-tract-cancer-patients
#2
Sreenivasulu Palugulla, Steven Aibor Dkhar, Smita Kayal, Sunil K Narayan
Purpose: The aim of the current study is to report our prospective experience on the prevalence of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients with digestive tract cancers treated with oxaliplatin-based combination therapy. Materials and Methods: A total of 219 patients scheduled to be treated with oxaliplatin-based combination therapy were prospectively examined at baseline and follow-up during the therapy between November 2014 and December 2016...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29325737/reliability-and-validity-of-the-chinese-version-neuropathic-pain-symptom-inventory-in-patients-with-colorectal-cancer
#3
Ling-Chun Lu, Sou-Yi Chang, Chieh-Yu Liu, Shiow-Luan Tsay
BACKGROUND/PURPOSE: Chemotherapy-induced peripheral neuropathy is a common consequence of chemotherapeutic treatments in patients with cancer. This study evaluated the validity and reliability of a Chinese version of the Neuropathic Pain Symptom Inventory (C-NPSI) in patients with colorectal cancer and chemotherapy-induced peripheral neuropathy. METHODS: This cross-sectional study recruited 106 patients from a cancer center in Northern Taiwan. The C-NPSI was obtained through the translation and back-translation of the original NPSI...
January 8, 2018: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29316888/the-preventive-effect-of-sensorimotor-and-vibration-exercises-on-the-onset-of-oxaliplatin-or-vinca-alkaloid-induced-peripheral-neuropathies-stop
#4
Fiona Streckmann, Maryam Balke, Helmar C Lehmann, Vanessa Rustler, Christina Koliamitra, Thomas Elter, Michael Hallek, Michael Leitzmann, Tilman Steinmetz, Petra Heinen, Freerk T Baumann, Wilhelm Bloch
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically relevant side effect of chemotherapy. Approximately 50% of all leukemia, lymphoma, colorectal- and breast cancer patients are affected. CIPN is induced by neurotoxic chemotherapeutic agents and can manifest with sensory and/or motor deficits. It is associated with significant disability and poor recovery. Common symptoms include pain, altered sensation, reduced or absent reflexes, muscle weakness, reduced balance control and insecure gait...
January 10, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29315285/strategies-to-manage-chemotherapy-induced-peripheral-neuropathy
#5
Manish R Sharma
No abstract text is available yet for this article.
December 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29282807/blocking-of-cytokines-signalling-attenuates-evoked-and-spontaneous-neuropathic-pain-behaviours-in-the-paclitaxel-rat-model-of-chemotherapy-induced-neuropathy
#6
S Al-Mazidi, M Alotaibi, T Nedjadi, A Chaudhary, M Alzoghaibi, L Djouhri
BACKGROUND: Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a serious dose-limiting neurotoxic effect of cancer drug treatment. The underlying mechanism(s) of this debilitating condition, which lacks effective drug treatment, is incompletely understood. However, neural-immune interactions, involving increased expression and release of cytokines, are believed to be involved. Here, we examined, in the paclitaxel rat model of CIPNP, whether plasma levels of 24 cytokines/chemokines change after paclitaxel treatment, and whether blocking of signalling of some of those cytokines would reverse/attenuate behavioural signs of CIPNP...
December 27, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29280313/efficacy-and-safety-of-oxycodone-naloxone-as-add-on-therapy-to-gabapentin-or-pregabalin-for-the-management-of-chemotherapy-induced-peripheral-neuropathy-in-korea
#7
Bong-Seog Kim, Jong-Youl Jin, Jung Hye Kwon, In Sook Woo, Yoon Ho Ko, Suk-Young Park, Hye-Jeong Park, Jin Hyung Kang
AIMS: To investigate the efficacy and safety of oxycodone/naloxone in patients with chemotherapy-induced peripheral neuropathy (CIPN) inadequately controlled with pregabalin or gabapentin. METHODS: This 4-week, multicenter, interventional, single-arm phase IV study included 72 Korean patients with CIPN inadequately controlled with pregabalin or gabapentin (Numeric Rating Scale 0-10; NRS ≥4 at baseline). In addition to pregabalin or gabapentin at existing doses, patients received 20/10 mg/day oxycodone/naloxone (up-titrated to 80/40 mg/day as needed)...
December 27, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29280005/goshajinkigan-for-prevention-of-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#8
REVIEW
Akira Kuriyama, Koji Endo
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) limits the dose of chemotherapy and reduces patients' quality of life. Goshajinkigan is a Japanese herbal medicine used to alleviate neuropathy and general pain. A clinical guideline for prevention and management of CIPN stated that the prophylactic efficacy of goshajinkigan against CIPN was inconclusive. We conducted a systematic review to examine whether goshajinkigan prevents CIPN in patients receiving neurotoxic chemotherapy...
December 26, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29278617/genome-wide-meta-analyses-identifies-novel-taxane-induced-peripheral-neuropathy-associated-loci
#9
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, William E Barlow, G Thomas Budd, Daniel O Stram, Christopher A Haiman, Xin Sheng, Li Yan, Gary Zirpoli, Song Yao, Chen Jiang, Kouros Owzar, Dawn Hershman, Kathy S Albain, Daniel F Hayes, Halle C Moore, Timothy J Hobday, James A Stewart, Abbas Rizvi, Claudine Isaacs, Muhammad Salim, Jule R Gralow, Gabriel N Hortobagyi, Robert B Livingston, Deanna L Kroetz, Christine B Ambrosone
OBJECTIVE: Taxane containing chemotherapy extends survival for breast cancer patients. However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or effectively treated. Using genome-wide analyses, we sought to identify common risk variants for TIPN. PATIENTS AND METHODS: Women with high-risk breast cancer enrolled in SWOG 0221 were genotyped using the Illumina 1M chip. Genome-wide analyses were performed in relation to ≥grade 3 Common Terminology Criteria for Adverse Events (CTCAE) neuropathy in European and African Americans...
February 2018: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/29277798/safety-and-efficacy-of-low-dose-nanoparticle-albumin-bound-paclitaxel-for-her2-negative-metastatic-breast-cancer
#10
Tsutomu Takashima, Hidemi Kawajiri, Takeo Nishimori, Seika Tei, Shigehiko Nishimura, Shigehito Yamagata, Shinya Tokunaga, Yoko Mizuyama, Takeshi Sunami, Kenji Tezuka, Katsumi Ikeda, Yoshinari Ogawa, Shinichiro Kashiwagi, Satoru Noda, Naoyoshi Onoda, Tetsuro Ishikawa, Shinzoh Kudoh, Minoru Takada, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175 mg/m2/3weeks regimen. PATIENTS AND METHODS: Patients having metastatic or inoperable HER2-negative breast cancer received 175 mg/m2 of nab-PTX every three weeks...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29274843/oxaliplatin-induced-changes-in-expression-of-transient-receptor-potential-channels-in-the-dorsal-root-ganglion-as-a-neuropathic-mechanism-for-cold-hypersensitivity
#11
Akiko Chukyo, Terumasa Chiba, Toshie Kambe, Ken Yamamoto, Kazuyoshi Kawakami, Kyoji Taguchi, Kenji Abe
Transient receptor potential (TRP) receptors are involved in the development of chemotherapy-induced peripheral neuropathic pain, which is a common side effect of selected chemotherapeutic agents such as oxaliplatin. However, the precise contribution of TRPs to this condition remains unknown. Cold hypersensitivity is the hallmark of oxaliplatin-induced neuropathy, so we used a preclinical model of oxaliplatin-induced cold hypersensitivity in rats to determine the effects of oxaliplatin on TRP channels. To this end, immunohistochemistry was used to examine TRP vanilloid 1 (TRPV1), TRP ankyrin 1 (TRPA1), and TRP melastatin 8 (TRPM8) expression in the rat dorsal root ganglion (DRG) after 4days of oxaliplatin treatment...
December 15, 2017: Neuropeptides
https://www.readbyqxmd.com/read/29262297/antiallodynic-and-antihyperalgesic-activity-of-new-3-3-diphenyl-propionamides-with-anticonvulsant-activity-in-models-of-pain-in-mice
#12
Anna Rapacz, Jolanta Obniska, Paulina Koczurkiewicz, Katarzyna Wójcik-Pszczoła, Agata Siwek, Anna Gryboś, Sabina Rybka, Aleksandra Karcz, Elżbieta Pękala, Barbara Filipek
Anticonvulsant drugs are used to treat a wide range of non-epileptic conditions, including chronic pain. The aim of the present experiments was to examine analgesic activity of three new 3,3-diphenyl-propionamides, which had previously demonstrated anticonvulsant activity in the MES (maximal electroshock seizure), scPTZ (subcutaneous pentylenetetrazole) and/or 6Hz (psychomotor seizure) tests in mice. Antinociceptive activity was examined in mouse models of acute pain (the hot plate test) and tonic pain (the formalin test) in mice...
December 17, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29243538/antineoplastic-agents-exacerbating-charcot-marie-tooth-disease-red-flags-to-avoid-permanent-disability
#13
M J Ibañez-Juliá, G Berzero, G Reyes-Botero, T Maisonobe, T Lenglet, M Slim, S Louis, A Balaguer, M Sanson, E Le Guern, P Latour, D Ricard, T Stojkovic, D Psimaras
BACKGROUND: Charcot Marie Tooth (CMT) disease is the most common form of hereditary neuropathy. Due to the high prevalence of mild and undiagnosed forms, patients with CMT disease may be exposed to severe neurotoxicity following the administration of neurotoxic chemotherapies. The aim of this report is to alert oncologists to the potential to precipitate severe irreversible peripheral neuropathies when administering neurotoxic compounds to undiagnosed CMT patients. MATERIAL AND METHODS: A retrospective research in the OncoNeuroTox database was performed (2010-2016), searching for patients with the diagnosis of chemotherapy-induced peripheral neuropathy (CIPN) and CMT disease...
December 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29243164/effects-of-exercise-during-chemotherapy-on-chemotherapy-induced-peripheral-neuropathy-a-multicenter-randomized-controlled-trial
#14
Ian R Kleckner, Charles Kamen, Jennifer S Gewandter, Nimish A Mohile, Charles E Heckler, Eva Culakova, Chunkit Fung, Michelle C Janelsins, Matthew Asare, Po-Ju Lin, Pavan S Reddy, Jeffrey Giguere, Jeffrey Berenberg, Shelli R Kesler, Karen M Mustian
PURPOSE: Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms...
December 14, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29229430/self-guided-online-cognitive-behavioral-strategies-for-chemotherapy-induced-peripheral-neuropathy-a-multicenter-pilot-randomized-wait-list-controlled-trial
#15
Robert Knoerl, Ellen M L Smith, Debra L Barton, David A Williams, Janean E Holden, John C Krauss, Beth LaVasseur
The purpose of this pilot, parallel, randomized-controlled trial was to examine the efficacy of a self-guided online cognitive and behaviorally-based pain management intervention (PROSPECT) to reduce "worst" pain for individuals with chronic painful chemotherapy-induced peripheral neuropathy (CIPN). Secondary outcomes included "average" pain, non-painful CIPN symptom severity, impression of change, and pain interference. Sixty patients with chronic painful CIPN were recruited from five outpatient academic and community cancer centers...
December 8, 2017: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/29224457/treatment-of-vincristine-induced-ileus-with-metoclopramide-a-case-report
#16
Hamidreza T Masoumi, Molouk Hadjibabaie, Morvarid Zarif-Yeganeh, Behrouz Khajeh, Ardeshir Ghavamzadeh
Introduction Acute lymphoblastic leukemia is an invasive malignancy which ought to be treated with several cytotoxic medications. Vincristine-based regimen is among the most commonly used regimens for the treatment of adult acute lymphoblastic leukemia. Peripheral neuropathy caused by vincristine provides a limitation in dose administration and can influence the treatment outcome and patient's quality of life. Case presentation Ileus and constipation occurred as a result of autonomic neuropathy in a 58-year-old man who underwent vincristine-based regimen for acute lymphoblastic leukemia treatment...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29219629/pharmacotherapy-options-for-managing-chemotherapy-induced-peripheral-neurotoxicity
#17
Guido Cavaletti, Paola Marmiroli
Prevention and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN) are clinically-relevant unmet needs. Despite extensive efforts at the preclinical and clinical levels, no effective pharmacological interventions are available, and this unsatisfactory situation reflects a combination of methodological issues and a lack of effectiveness of the tested drugs. Areas covered: This non-systematic, but unbiased review is based on published papers available in PubMed and screened using the broad search string [chemotherapy (and) neuropathy (and) treatment] to analyze the reported data...
December 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29219049/role-of-mitochondrial-mechanism-in-chemotherapy-induced-peripheral-neuropathy
#18
Mohammad Waseem, Pooja Kaushik, Heena Tabassum, Suhel Parvez
BACKGROUND: Even though chemotherapeutic regimens shows considerable importance, it may cause progressive, continuing and sometimes irreversible peripheral neuropathy. Chemotherapy induced peripheral neuropathy (CIPN) comprises of sensory abnormalities that are most distress issues. The mechanism associated with CIPN pathogenesis is not completely revealed and is treatment is still questionable. The purpose of this review was to investigate the role of mitochondria in CIPN. METHODS: This review is literature based that describes the mitochondrial mechanism underlying CIPN and the neuropathic complications associated with different antineoplastic agents...
December 7, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/29206213/duloxetine-protects-against-oxaliplatin-induced-neuropathic-pain-and-spinal-neuron-hyperexcitability-in-rodents
#19
Woojin Kim, Yeongu Chung, Seunghwan Choi, Byung-Il Min, Sun Kwang Kim
Oxaliplatin is a widely used chemotherapy agent, but induces serious peripheral neuropathy. Duloxetine is a dual reuptake inhibitor of serotonin and norepinephrine, and is shown to be effective against pain. However, whether and how duloxetine can attenuate oxaliplatin-induced allodynia in rodents is not clearly understood. A single injection of oxaliplatin (6 mg/kg, intraperitoneal; i.p.) induced a cold and mechanical allodynia, which was assessed by acetone and von Frey filament tests, respectively. When significant allodynic signs were observed, three different doses of duloxetine (10, 30, and 60 mg/kg, i...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29204710/chemotherapy-related-neuropathic-symptom-management-a-randomized-trial-of-an-automated-symptom-monitoring-system-paired-with-nurse-practitioner-follow-up
#20
Noah Allan Kolb, Albert Gordon Smith, John Robinson Singleton, Susan L Beck, Diantha Howard, Kim Dittus, Summer Karafiath, Kathi Mooney
PURPOSE: The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms. METHODS: Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies...
December 5, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
28478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"